CGP-42112 acetate NEW
| Price | $89 | $310 | $447 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-12 |
Product Details
| Product Name: CGP-42112 acetate | Purity: 99.94% |
| Supply Ability: 10g | Release date: 2026/06/12 |
Product Introduction
Bioactivity
| Name | CGP-42112 acetate |
| Description | CGP-42112 acetate is a potent angiotensin receptor AT2 agonist that inhibits the increase in protein kinase A activity produced by LPS. |
| In vitro | At concentrations of ≥1 nM, CGP-42112 acetate significantly inhibits cGMP production from the basal value and also inhibits TH-enzyme activity from the basal value. The inhibitory effects of CGP-42112 acetate on TH-enzyme activity and cGMP production are nullified by PD123319 (AT(2)-R antagonist), while CV-11974 (AT(1)-R antagonist) is ineffective[1].[125I]CGP-42112 acetate selectively binds to the AT2 angiotensin II receptor subtype. The binding affinity of [125I]CGP-42112 acetate is higher in the brain than in the adrenal. Beta-mercaptoethanol enhances [125I]CGP-42112 acetate binding in the brain but does not alter its binding in the adrenal[2].The high-affinity binding of [125I]CGP-42112 acetate (Kd = 0.07-0.3 nM, depending on the area studied) is selective for AT2 receptors. This selectivity is demonstrated by the lack of competition with the AT1 ligand losartan and competition by the AT2 ligands PD 123177 and unlabeled CGP-42112 acetate, as well as the non-selective peptides Ang II and angiotensin III (Ang III)[3]. |
| In vivo | Intravenous infusions of CGP-42112 acetate (0.1 and 1 mg kg-1 min-1) and PD 123319 (0.36 and 1 mg kg-1 min-1) shifted the upper limit of CBF autoregulation toward higher blood pressures without affecting baseline CBF[4]. |
| Storage | Store at low temperature,Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 50 mg/mL (44.95 mM), Sonication is recommended. |
| Keywords | CGP42112acetate(127060757Freebase) | AT2 receptor |
| Inhibitors Related | Losartan potassium | Tranilast | Enalapril Maleate | Telmisartan | Lisinopril dihydrate | Sacubitril/Valsartan | Benzyl benzoate | Irbesartan | Losartan | Ramipril | Diisononyl phthalate | Captopril |
| Related Compound Libraries | Bioactive Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP2Y
|
Xi an Biohorlden Industry Trade Co Ltd
|
2026-07-07 | ||
|
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-27 | ||
| $1.00 |
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-07-07 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY